When: ~2 weeks before Q3 print in late October/early November

Then: Stage 10-15% trim over 3-5 sessions

When: 5-7 sessions without breakout trigger firing

Then: Reset anchor to $144-146

HOLD - maintain current weight; do not add into tested resistance; wait for breakout confirmation above 153.86 or pullback to 146-148 zone with RSI and volume support; stops should be placed at 142.35 or 140.84, not at 148.11

• MACD histogram at negative 0.09 signals momentum inflection with fresh capital deployment into tested resistance inappropriate
• Price rejected at 152-153 zone three times constitutes tested resistance, not bull flag formation
• Entry at 150.93 with stop at 148.11 provides only $2.82 cushion (less than 1 ATR of 3.57)
• Forward P/E of 15.3 with PEG of 2.2 represents fully priced name, not misunderstood value
• Biktarvy peak sales of $13B faces patent-cliff risk in late 2020s
• Lenacapavir royalty-free licensing in 120 countries contradicts aggressive upside scenario economics
• Immunomedics acquisition resulted in $9B impairment charges documenting capital allocation overpayment history
• Morgan Stanley Overweight rating carries limited signal given sell-side incentive structure
• Breakout trading strategy preferred: enter on confirmation, not before; patient entry on breakout retest still profitable

→ vs aggressive: MACD histogram at negative 0.09 is not statistical noise—it flags momentum inflection requiring caution on new capital deployment

→ vs aggressive: Rejected tests at 152-153 on declining volume shows buyers cannot generate demand to break through, not exhausted sellers

→ vs aggressive: Stop at 148.11 contradicts conviction thesis; cannot demand tight stop while claiming structural setup justifies entry

→ vs aggressive: 5% FCF yield attractive against 5% ten-year only if FCF is perpetual and multiple holds; defensive does not mean immune to de-rating

→ vs aggressive: Lenacapavir royalty-free licensing in 120 countries is revenue Gilead will never collect, contradicting moat economics thesis

→ vs aggressive: Accelerating buybacks at high valuations may confess scarce internal capital allocation opportunities rather than signal undervaluation

HOLD at current neutral weight with hybrid scaling approach—1% position size on confirmed breakout above 153.86 with volume above 7 million shares, additional 1-2% on pullback to 146-148 with RSI above 50 and close back above 10-EMA. Reframe the 148.11 hard stop to either a 10-EMA trailing pivot at 149.70 or a structural trailing stop at 145.50 for existing positions. Keep total exposure neutral pending resolution, with pullback as primary add location and breakout as secondary with smaller sizing.

• MACD histogram reading of minus 0.09 is a yellow flag, not red—do not initiate fresh capital into resistance; wait for histogram re-cross or price pullback
• Bull flag versus supply exhaustion at 152-153 is a genuine coin flip with three rejections consistent with both interpretations; waiting for resolution is correct
• Macro environment favors defensive compounders—GILD's beta of 0.35 and FCF yield north of 5 percent beating the 10-year Treasury is a real relative-value signal
• Lenacapavir royalty-free licensing in 120 countries is neutral to slightly negative for income statement near-term despite strategic moat value
• Buybacks of 1.92 billion chosen over debt paydown, acquisitions, or dividend increase is moderately bullish information, not routine capital return
• GILD fairly priced to modestly cheap on forward P/E of 15.3, fairly priced on PEG of 2.2, not cheap on historical basis—neither 15% upside nor 15% downside is base case
• Breakout entry at 153.86 with 148.11 stop yields roughly 5.75 upside against 5.75 downside (1-to-1 risk-reward); pullback entry at 146-148 with 142.35 stop yields 5-7 upside against 3-6 downside (1.5-to-1 or better)
• Assumed 55% breakout probability with 4% follow-through and 45% pullback probability with 4% bounce from 146—expected returns roughly similar but pullback entry has lower variance
• Q3 earnings season approaching as binary event window with high guidance risk but positive HIV franchise revision potential
• GILD could be buyer or target in biotech M&A consolidation—target scenario historically trades at 25-40% premium; maintain modest sizing without dismissing optionality

→ vs aggressive: Wrong to dismiss MACD histogram reading of minus 0.09 as pure noise when it specifically flags inflection; correct observation about regime confirmation does not justify ignoring the indicator at resistance

→ vs aggressive: Internally inconsistent—wants to buy at 150.93 with tight 2.82 stop (less than 1 ATR) against ATR of 3.57, but also argues pullbacks to 146-148 are buying opportunities; cannot want both tight entry and expect to buy lower

→ vs aggressive: Overstating lenacapavir strategic value—royalty-free licensing is arithmetic revenue loss; strategic moat and share-price returns are not equivalent over 1-3 quarter horizon

→ vs aggressive: HOLD recommendation as cop-out is rhetorically appealing but empirically weak; two-sided setup genuinely justifies neutral weight pending resolution

→ vs conservative: Wrong to treat MACD histogram minus 0.09 as confirmed signal; both lines well above zero confirms regime, not regime change

→ vs conservative: Overcorrecting on defensive utility—defensive does not mean immune is technically correct but underweights the relative-value case where GILD FCF yield equals cash yield with upside optionality

→ vs conservative: Too dismissive on buybacks; management choosing buybacks over three other capital allocation options is information, not routine capital return

→ vs conservative: Internally inconsistent—wants to maintain position with structural floor at 140-142 but also wants stop 5-7 dollars below that; if floor believed, stop should be at or just below 142